Neoliberalism, conflict of interest, and the governance of health research in Canada

Open Medicine

Volumn 4, Issue 1, 2010, Pages

  Lewis, Steven ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956020528     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Note

References (17)

1. Munro M. Scientists protest appointment of Pfizer boss to health panel. Ottawa Citizen. 2009; Dec 7. Available: http://www.ottawacitizen. com/technology/Scientists+protest+appointment+Pf izer+boss+health+panel/2313837/story.html (accessed 2010 Jan 24).
2. Lewis S. Where there's smoke, there's Pfizer: Sparks fly over recent CIHR appointment. Essays (online). 2009. Longwoods Publishing. Available: http://longwoods.com/product.php?productid=21198&page=1 (accessed 2010 Jan 29).
3. Sharma AM. Appointment of Dr. Bernard Prigent to the Canadian Institutes of Health Research (CIHR) Governing Council (GC). Essays (online). 2009 Longwoods Publishing. Available: http://longwoods.com/product.php?productid=21205&page=1 (accessed 2010 Jan 29).
4. Baylis F. An intractable conflict of interest. Essays (online). 2009. Longwoods Publishing. Available: http://longwoods.com/product.php?productid=21200&page=1 (accessed 2010 Jan 29).
5. Lewis S. Well I declare: The emasculation of conflict-of-interest. Essays (online). 2009. Longwoods Publishing. Available: http://longwoods.com/product.php?productid=21200&page=1 (accessed 2010 Jan 29).
6. Cassels A. Pfizer eyes Canada: World's biggest drug maker sets its sights on Canadian healthcare. Common Ground Jan 2010. Available: http://www.commonground.ca/iss/222/cg222_cassels.shtml (accessed 2010 Feb 1).
7. Canada. Parliament. House of Commons Standing Committee on Health. Evidence of Proceedings, meeting no. 47, November 30, 2009 http://www2.parl.gc.ca/HousePublications/Publication. aspx?DocId=4275165&Language=E&Mode=1&Parl=40&S es=2 and meeting no. 49, December 7, 2009 http://www2.parl. gc.ca/HousePublications/Publication.aspx?DocId=4319116&Lan guage=E&Mode=1&Parl=40&Ses=2.
8. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-333.
9. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med 2009;169(21):1976-1985.
10. Angell M. The truth about the drug companies. New York: Random House Trade Paperbacks; 2005.
11. No place for (registered) lobbyists [editorial]. N Y Times 2009 Dec 3. Available: http://www.nytimes.com/2009/12/04/opinion/04fri4.html?_r=1&th&emc=th (accessed 2010 Jan 23).
12. Wilson D. Harvard teaching hospitals cap outside pay. N Y Times 2010 Jan 2. Available: http://www.nytimes.com/2010/01/03/health/research/03hospital.html (accessed 2010 Jan 24).
13. Gillick MR. Controlling off-label medication use. Ann Intern Med 2009;150(5):344-347.
14. United States General Accounting Office. New drug development: Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. Report GAO-07-49, Nov 2006. Available: http://www.gao.gov/new.items/d0749.pdf (accessed 2010 Jan 24).
15. Patented Medicine Price Review Board. Non-patented prescription drug prices reporting. Canadian and foreign price trends. Ottawa: PMPRB; 2006.
16. Canadian Institutes of Health Research. CIHR's commercialization and innovation strategy, November 2005. Available: http://www.cihr-irsc.gc.ca/e/30162.html (accessed 2010 Jan 28).
17. O'Reilly C, Capaccio T. Pfizer agrees to record criminal fine in fraud probe. Bloomberg News 2009; Sept 2. Available: http://www.bloomberg.com/apps/news?pid=20601103&sid=a4h7V5lc_xXM (accessed 2010 Jan 24).